Structure-based evolution of subtype-selective neurotensin receptor ligands

Area of Science:

• Medicinal Chemistry
• Neuroscience
• Pharmacology

Background:

• Neurotensin receptor 2 (NTS2) agonists offer potential for neuropathic pain relief via μ-opioid-independent pathways.
• Understanding structure-activity relationships (SARs) of neurotensin (NT) analogs is crucial for subtype-selective ligand design.

Purpose of the Study:

• To design and synthesize novel NTS2-selective ligands.
• To explore tyrosine bioisosteres for enhanced NTS2 selectivity and affinity.

Main Methods:

• Modification of the NT(8-13) peptide backbone using β(2)-amino acids, heterocyclic bioisosteres, and peptoid analogs.
• Asymmetric synthesis of a 5-substituted azaindolylalanine as a tyrosine bioisostere.
• Affinity and selectivity profiling of synthesized compounds against NTS1 and NTS2 receptors.

Main Results:

• Developed an efficient asymmetric synthesis for a novel tyrosine bioisostere.
• Identified compound 2a, [(S)-3-(pyrazolo[1,5-a]pyridine-5-yl)-propionyl(11)]NT(8-13), with high NTS2 affinity (4.8 nm) and ~30-fold selectivity over NTS1.
• The (R)-epimer 2b demonstrated significantly higher NTS1 selectivity (>600-fold) despite lower NTS2 affinity.

Conclusions:

• Novel NTS2-selective ligands were successfully developed using bioisosteric replacement of tyrosine.
• Compound 2a represents a promising lead for developing μ-opioid-independent treatments for neuropathic pain.
• Stereochemistry plays a critical role in achieving both high affinity and subtype selectivity for NTS2 ligands.